The field of research ethics, once focused on protecting vulnerable subjects from harm, has evolved. A cultural emphasis on individual liberty, exemplified by the "right-to-try" movement, has created a new ethos where patients demand access to experimental treatments, even with high risks.

The pro-peptide argument isn't that these substances are proven cures, but that a regulated "white market" is safer than the current gray market. By moving production to GMP-certified compounding pharmacies under FDA oversight, the goal is to reduce harm from a dodgy, unregulated supply chain that already exists.

The requirement for prescriptions for many safe drugs stems from a paternalistic medical culture that distrusts patients, not from genuine safety concerns. This drives up costs and creates unnecessary barriers, similar to how the establishment initially resisted home pregnancy and COVID tests.

New obesity medications are for a chronic disease, not aesthetics. Using them for short-term goals, like fitting into a wedding dress, misappropriates medicine, contributes to shortages, and reinforces the harmful idea that obesity is merely a lifestyle choice.

The conviction of an ADHD startup founder for over-prescribing Adderall illustrates the danger of optimizing healthcare for conversions. It proves that a doctor's assessment and incentive for quality care is a critical patient safety feature, not a bug to be removed by tech.

As AI models become adept at identifying novel or experimental treatments for individuals, it will create mounting pressure on the medical regulatory system. Patients, armed with compelling, AI-generated arguments for a specific therapy, will increasingly challenge the gates kept by establishments, potentially forcing an evolution of the social contract around access to unproven medicines ('right to try').

Objecting to GLP-1s for outsourcing discipline is a flawed argument. Medicine has always sought to reduce human struggle, from anesthesia to antibiotics. Viewing GLP-1s as tools that improve biological function to free up human potential for other endeavors is consistent with this history.

Hart's drug policy vision involves legal regulation, not a free-for-all. It includes user licensing for potent substances, government quality and dose control to prevent overdoses, and public education on safer consumption methods to mitigate risks.

The therapeutic benefits of psychedelics are maximized when approached with professional protocols. This includes careful preparation, setting a clear intention for the session, and having proper accompaniment from a guide, which is crucial for safety and effectiveness.